DOP2024000019A - Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer - Google Patents
Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncerInfo
- Publication number
- DOP2024000019A DOP2024000019A DO2024000019A DO2024000019A DOP2024000019A DO P2024000019 A DOP2024000019 A DO P2024000019A DO 2024000019 A DO2024000019 A DO 2024000019A DO 2024000019 A DO2024000019 A DO 2024000019A DO P2024000019 A DOP2024000019 A DO P2024000019A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pi3k
- inhibit
- methods
- compounds
- treating cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231156P | 2021-08-09 | 2021-08-09 | |
| PCT/US2022/039674 WO2023018636A1 (en) | 2021-08-09 | 2022-08-08 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000019A true DOP2024000019A (es) | 2024-03-15 |
Family
ID=83188497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000019A DOP2024000019A (es) | 2021-08-09 | 2024-02-02 | Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240343728A1 (https=) |
| EP (1) | EP4363414A1 (https=) |
| JP (1) | JP2024533975A (https=) |
| KR (1) | KR20240051953A (https=) |
| CN (1) | CN118159534A (https=) |
| AU (1) | AU2022325819A1 (https=) |
| CA (1) | CA3227902A1 (https=) |
| CL (1) | CL2024000327A1 (https=) |
| CO (1) | CO2024000448A2 (https=) |
| CR (1) | CR20240045A (https=) |
| DO (1) | DOP2024000019A (https=) |
| EC (1) | ECSP24008488A (https=) |
| GE (1) | GEAP202416449A (https=) |
| IL (1) | IL310588A (https=) |
| JO (1) | JOP20240020A1 (https=) |
| MA (1) | MA63885B1 (https=) |
| MX (1) | MX2024000708A (https=) |
| PE (1) | PE20240652A1 (https=) |
| WO (1) | WO2023018636A1 (https=) |
| ZA (1) | ZA202401094B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202541794A (zh) | 2022-11-02 | 2025-11-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點 |
| KR20260005985A (ko) | 2023-05-05 | 2026-01-12 | 일라이 릴리 앤드 캄파니 | Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염 |
| WO2025036439A1 (en) * | 2023-08-16 | 2025-02-20 | Laekna Pharmaceutical Ningbo Co., Ltd. | Multicyclic compounds and their use as pi3k alpha inhibitors |
| WO2025144931A1 (en) * | 2023-12-27 | 2025-07-03 | Genesis Therapeutics, Inc. | Methods for treating cancer |
| WO2025201503A1 (en) * | 2024-03-28 | 2025-10-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0515025D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| SI2170906T1 (sl) * | 2007-06-26 | 2013-07-31 | Ucb Pharma, S.A. | Zliti derivati tiazola, kot inhibitorji kinaze |
| JP2012521354A (ja) * | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| WO2011163195A1 (en) * | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| HK1232227A1 (zh) * | 2014-07-04 | 2018-01-05 | Lupin Limited | 作为pi3k抑制剂的喹嗪酮衍生物 |
| AU2016287463B2 (en) * | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
-
2022
- 2022-08-08 US US18/293,823 patent/US20240343728A1/en active Pending
- 2022-08-08 PE PE2024000156A patent/PE20240652A1/es unknown
- 2022-08-08 WO PCT/US2022/039674 patent/WO2023018636A1/en not_active Ceased
- 2022-08-08 KR KR1020247007455A patent/KR20240051953A/ko active Pending
- 2022-08-08 MA MA63885A patent/MA63885B1/fr unknown
- 2022-08-08 JP JP2024506896A patent/JP2024533975A/ja active Pending
- 2022-08-08 MX MX2024000708A patent/MX2024000708A/es unknown
- 2022-08-08 GE GEAP202416449A patent/GEAP202416449A/en unknown
- 2022-08-08 AU AU2022325819A patent/AU2022325819A1/en active Pending
- 2022-08-08 CN CN202280062281.6A patent/CN118159534A/zh active Pending
- 2022-08-08 IL IL310588A patent/IL310588A/en unknown
- 2022-08-08 EP EP22764505.8A patent/EP4363414A1/en active Pending
- 2022-08-08 CR CR20240045A patent/CR20240045A/es unknown
- 2022-08-08 CA CA3227902A patent/CA3227902A1/en active Pending
-
2024
- 2024-01-18 CO CONC2024/0000448A patent/CO2024000448A2/es unknown
- 2024-02-01 EC ECSENADI20248488A patent/ECSP24008488A/es unknown
- 2024-02-01 JO JOJO/P/2024/0020A patent/JOP20240020A1/ar unknown
- 2024-02-02 CL CL2024000327A patent/CL2024000327A1/es unknown
- 2024-02-02 ZA ZA2024/01094A patent/ZA202401094B/en unknown
- 2024-02-02 DO DO2024000019A patent/DOP2024000019A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118159534A (zh) | 2024-06-07 |
| US20240343728A1 (en) | 2024-10-17 |
| CO2024000448A2 (es) | 2024-02-15 |
| IL310588A (en) | 2024-04-01 |
| MX2024000708A (es) | 2024-02-08 |
| MA63885A1 (fr) | 2024-09-30 |
| KR20240051953A (ko) | 2024-04-22 |
| MA63885B1 (fr) | 2025-01-31 |
| CL2024000327A1 (es) | 2024-08-09 |
| ECSP24008488A (es) | 2024-05-31 |
| JP2024533975A (ja) | 2024-09-18 |
| CA3227902A1 (en) | 2023-02-16 |
| GEAP202416449A (en) | 2024-04-25 |
| CR20240045A (es) | 2024-02-20 |
| AU2022325819A1 (en) | 2024-02-29 |
| EP4363414A1 (en) | 2024-05-08 |
| WO2023018636A1 (en) | 2023-02-16 |
| ZA202401094B (en) | 2025-05-28 |
| PE20240652A1 (es) | 2024-04-04 |
| JOP20240020A1 (ar) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000271A (es) | Derivados de la urea que pueden ser utilizados para tratar el cáncer | |
| DOP2024000019A (es) | Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| UY38742A (es) | Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida | |
| ECSP24044340A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| CL2025004052A1 (es) | Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer | |
| ECSP13012752A (es) | Imidazopiridazinas sustituidas | |
| CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
| CO2024017767A2 (es) | Sales de inhibidores de sos1 | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| CO2022014886A2 (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 | |
| UY30880A1 (es) | 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones | |
| UY39819A (es) | Métodos para tratar el cáncer | |
| MX2025004911A (es) | Terapia de combinacion para tratar el cancer | |
| AR126147A1 (es) | Derivados de urea para tratar el cáncer | |
| MX2021008748A (es) | Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias. | |
| GEAP202416416A (en) | Urea derivatives which can be used to treat cancer | |
| CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR132326A1 (es) | Protacs para irak4 | |
| AR123760A1 (es) | Métodos para tratar el cáncer | |
| AR123576A1 (es) | Métodos para tratar el cáncer |